Kip leads the translational efforts at Dewpoint; he is an expert in oncology, immuno-oncology, preclinical development, and translational science – having contributed to several INDs. He has authored >30 articles in peer-reviewed journals and delivered invited oral presentations at international meetings such as AACR, SITC and FOCIS.
He has worked for multiple biotech companies in the Boston area including Merrimack Pharmaceuticals, Infinity Pharmaceuticals, Epizyme Therapeutics and Synlogic Therapeutics, mostly in the oncology and inflammatory disease spaces. During this time, he has worked on >15 drug development programs across multiple disease areas, headed several groups in both Biology and In Vivo Pharmacology, led multiple programs at various stages of pre-clinical development, served as the Biomarker Lead for clinical stage programs in both oncology and rare disease, as well as contributing to 8 IND and 6 patent filings.
Kip is a native of Milwaukee, Wisconsin and went to college at the University of Wisconsin-Madison. He did his Ph.D. in cancer cell biology at SUNY Upstate Medical University in Syracuse, NY and his post-doctoral training in oncology at the National Cancer Institute in Bethesda, MD and at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, MA.
Kip lives in Nahant (and has for the past 15 years), an island off the coast of the North Shore of Massachusetts, with his wife and three sons. In his free time, he enjoys coaching his son’s football and basketball teams and staying active (CrossFit, running, hiking, snowboarding/snowshoeing, golf and softball).